Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 2
Submit an article Journal homepage
229
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Bilateral phrenic nerve palsy induced by subcutaneous bortezomib in a patient with newly diagnosed multiple myeloma: first case reported

Meritxell Lópeza Department of Hematology, Hospital Universitari Mútua Terrassa, Terrassa, Spain
,
Xavier Martínez Lacasab Department of Medicine, Hospital Universitari Mútua Terrassa, Terrassa, Spain
,
Josep M. Martía Department of Hematology, Hospital Universitari Mútua Terrassa, Terrassa, Spain
,
Ana Muntañolaa Department of Hematology, Hospital Universitari Mútua Terrassa, Terrassa, Spain
,
Mar Fernándezc Intensive Care Unit, Hospital Universitari Mútua Terrassa, Terrassa, Spain
,
Sonia Huertasd Department of Neurology, Hospital Universitari Mútua Terrassa, Terrassa, Spain
,
Sílvia Saumella Department of Hematology, Hospital Universitari Mútua Terrassa, Terrassa, Spain
,
Isabel De Diegoa Department of Hematology, Hospital Universitari Mútua Terrassa, Terrassa, Spain
,
Gabriela Bustamantea Department of Hematology, Hospital Universitari Mútua Terrassa, Terrassa, Spain
,
Alba Mesaa Department of Hematology, Hospital Universitari Mútua Terrassa, Terrassa, Spain
,
Marta Caneta Department of Hematology, Hospital Universitari Mútua Terrassa, Terrassa, Spain
,
Marta Juliàa Department of Hematology, Hospital Universitari Mútua Terrassa, Terrassa, Spain
&
Ferran Vall-Lloveraa Department of Hematology, Hospital Universitari Mútua Terrassa, Terrassa, SpainCorrespondence[email protected]
 show all
Pages 482-484 | Received 16 Feb 2016, Accepted 22 May 2016, Published online: 27 Jun 2016

References

  • Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165–172.
  • Richardson PG, Delforge M, Beksac M, et al. IMWG guidelines for the management of treatment-emergent peripheral neuropathy in multiple myeloma (MM). Leukemia. 2012;26:595–608.
  • Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009;27:3518–3525.
  • Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63:419–437.
  • Moureau P, Pylypenko H, Grosicki S, et al. Subcutaneus versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–440.
  • Kumar S, Laubach JP, Sonneveld P, et al. Bortezomib (Btz)-induced peripheral neuropathy (BiPN) in previously untreated MM: impact of dexamethasone (Dex) schedule. Clin Lymphoma Myeloma Leukemia. 2013;13:S235.
  • Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112:1593–1599.
  • Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010;95:311–319.
  • Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol. 2007;204:317–325.
  • Ravaglia S, Corso A, Piccolo G, et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol. 2008;119:2507–2512.
  • Chim CS, Ooi GC. Bulbar palsy in multiple myeloma. Haematologica. 2005;90:ECR42.
  • Landowski TH, Megli CJ, Nullmeyer KD, et al. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res. 2005;65:3828–3836.
  • Nizeica V, Collet P, Marott H. Bortezomib induced a phrenic palsy in a multiple myeloma patient. Ann Hematol. 2013;92:1135–1136.
  • Lanzani F, Mattavelli L, Frigeni B, et al. Role of a pre-existing neuropathy on the course of Bortezomib-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2008;13: 267–274.
  • Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113–3120.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.